Inhibikase Therapeutics Stock Probability of Future Stock Price Finishing Over 23.78
| IKT Stock | USD 3.44 0.20 6.17% |
Inhibikase |
Inhibikase Therapeutics Target Price Odds to finish over 23.78
The tendency of Inhibikase Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 23.78 or more in 90 days |
| 3.44 | 90 days | 23.78 | close to zero percent |
Based on a normal probability distribution, the odds of Inhibikase Therapeutics to move over $ 23.78 or more in 90 days from now is close to zero percent (This Inhibikase Therapeutics probability density function shows the probability of Inhibikase Stock to fall within a particular range of prices over 90 days) . Probability of Inhibikase Therapeutics price to stay between its current price of $ 3.44 and $ 23.78 at the end of the 90-day period is under 4.
Considering the 90-day investment horizon the stock has the beta coefficient of 1.46 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Inhibikase Therapeutics will likely underperform. Moreover Inhibikase Therapeutics has an alpha of 1.7009, implying that it can generate a 1.7 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Inhibikase Therapeutics Price Density |
| Price |
Predictive Modules for Inhibikase Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Inhibikase Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Inhibikase Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Inhibikase Therapeutics is not an exception. The market had few large corrections towards the Inhibikase Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Inhibikase Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Inhibikase Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.70 | |
β | Beta against Dow Jones | 1.46 | |
σ | Overall volatility | 0.73 | |
Ir | Information ratio | 0.25 |
Inhibikase Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Inhibikase Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Inhibikase Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Inhibikase Therapeutics is way too risky over 90 days horizon | |
| Inhibikase Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 260.5 K. Reported Net Loss for the year was (19.03 M) with loss before taxes, overhead, and interest of (8.26 M). | |
| Inhibikase Therapeutics has about 32.21 M in cash with (18.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28. | |
| Inhibikase Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of 21853 shares by Milton Werner of Inhibikase Therapeutics at 2.02 subject to Rule 16b-3 |
Inhibikase Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Inhibikase Stock often depends not only on the future outlook of the current and potential Inhibikase Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Inhibikase Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.3 M | |
| Cash And Short Term Investments | 13.3 M |
Inhibikase Therapeutics Technical Analysis
Inhibikase Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Inhibikase Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Inhibikase Therapeutics. In general, you should focus on analyzing Inhibikase Stock price patterns and their correlations with different microeconomic environments and drivers.
Inhibikase Therapeutics Predictive Forecast Models
Inhibikase Therapeutics' time-series forecasting models is one of many Inhibikase Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Inhibikase Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Inhibikase Therapeutics
Checking the ongoing alerts about Inhibikase Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Inhibikase Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Inhibikase Therapeutics is way too risky over 90 days horizon | |
| Inhibikase Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 260.5 K. Reported Net Loss for the year was (19.03 M) with loss before taxes, overhead, and interest of (8.26 M). | |
| Inhibikase Therapeutics has about 32.21 M in cash with (18.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28. | |
| Inhibikase Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of 21853 shares by Milton Werner of Inhibikase Therapeutics at 2.02 subject to Rule 16b-3 |
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.